INI1 Negative Malignant Tumors (With PI Approval) clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 6 months to 30 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
Our lead scientists for INI1 Negative Malignant Tumors (With PI Approval) research studies include Alyssa Reddy, MD.